Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

BUY
$191.17 - $325.63 $1.23 Million - $2.1 Million
6,450 Added 91.68%
13,485 $4.39 Million
Q4 2023

Jan 16, 2024

SELL
$160.99 - $215.69 $291,230 - $390,183
-1,809 Reduced 20.45%
7,035 $1.34 Million
Q3 2023

Oct 24, 2023

SELL
$194.33 - $283.97 $4.79 Million - $7 Million
-24,668 Reduced 73.61%
8,844 $1.76 Million
Q2 2023

Jul 25, 2023

BUY
$223.05 - $302.68 $6.38 Million - $8.66 Million
28,603 Added 582.66%
33,512 $9.56 Million
Q1 2023

Apr 14, 2023

SELL
$175.41 - $217.92 $1.11 Million - $1.38 Million
-6,340 Reduced 56.36%
4,909 $1.06 Million
Q4 2022

Feb 08, 2023

SELL
$204.38 - $296.82 $855,943 - $1.24 Million
-4,188 Reduced 27.13%
11,249 $2.31 Million
Q3 2022

Oct 25, 2022

BUY
$195.21 - $310.53 $1.72 Million - $2.73 Million
8,806 Added 132.8%
15,437 $4.29 Million
Q2 2022

Aug 12, 2022

BUY
$115.91 - $214.48 $230,313 - $426,171
1,987 Added 42.79%
6,631 $1.27 Million
Q1 2022

May 11, 2022

BUY
$127.96 - $207.36 $10,364 - $16,796
81 Added 1.78%
4,644 $963,000
Q4 2021

Feb 08, 2022

SELL
$165.13 - $241.83 $782,881 - $1.15 Million
-4,741 Reduced 50.96%
4,563 $814,000
Q3 2021

Nov 02, 2021

SELL
$163.99 - $235.57 $278,291 - $399,762
-1,697 Reduced 15.43%
9,304 $1.92 Million
Q2 2021

Aug 11, 2021

BUY
$131.45 - $201.49 $983,245 - $1.51 Million
7,480 Added 212.44%
11,001 $2.09 Million
Q1 2021

May 14, 2021

BUY
$92.73 - $142.05 $145,400 - $222,734
1,568 Added 80.29%
3,521 $459,000
Q4 2020

Feb 12, 2021

BUY
$67.44 - $103.72 $131,710 - $202,565
1,953 New
1,953 $203,000
Q3 2019

Nov 07, 2019

SELL
$29.71 - $55.23 $440,747 - $819,337
-14,835 Closed
0 $0
Q2 2019

Aug 06, 2019

BUY
$29.73 - $66.02 $441,044 - $979,406
14,835 New
14,835 $847,000

Others Institutions Holding SWAV

About Shockwave Medical, Inc.


  • Ticker SWAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,927,100
  • Description
  • ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease ...
More about SWAV
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.